Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | IDH1 | O75874 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163224 | 0.87 | NPC1 (0.41) | NPC1RAB9AGSK3BIDH1ROCK2 | |
| SCHEMBL4168076 | 0.85 | MAPT (0.46) | NPC1RAB9AIDH1MAPTPOLB | |
| SCHEMBL4154216 | 0.83 | SHMT2 (0.38) | IDH1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL10967371 | 0.81 | PIM1 (0.38) | IDH1KDM4E | |
| SCHEMBL4156006 | 0.79 | CCNA2 (0.35) | IDH1PDE5AEGFRKDM4EBLM | |
| SCHEMBL4164023 | 0.77 | ALDH1A1 (0.39) | NPC1RAB9AIDH1POLBMEN1 | |
| SCHEMBL4159917 | 0.76 | DYRK1A (0.47) | NPC1RAB9AMAPTPOLBMEN1 | |
| SCHEMBL4157701 | 0.74 | PARP1 (0.42) | IDH1MAPTPOLBKDM4EALDH1A1 | |
| SCHEMBL4148683 | 0.73 | ALDH1A1 (0.42) | NPC1RAB9AIDH1MAPTPOLB | |
| SCHEMBL11018475 | 0.72 | KDM4E (0.56) | NPC1RAB9AMAPTROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUG-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | APP, PSEN2, PSEN1 | NPC1 200/4885RAB9A 2510/4885GSK3B 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.